Login
Order
Patients
Providers
Partners
CARE
Science
Company
Overview
Take Action
Our Tests
How to Submit a Sample
Billing + Insurance
Blog
Overview
Our Tests
Order Placement
Resources
Our Science
Overview
Pharma Services
Academic Partners
Sponsored Testing Programs - AmbryLink
CARE Overview
CARE for Cancer
Overview
Classifi™
Our Technology
Our Research
Collaborations
Overview
Team
Our Story
Careers
Press Releases
Media Relations
Videos
News
Events
Contact
Hereditary Cancer
Heart Conditions
Neurological Conditions
Rare Conditions
Clinical Tests
Oncology
Cardiology
Neurology
Exome + General Genetics
Featured Add-Ons
+RNAinsight®
(concurrent DNA/RNA Testing)
Patient for Life Program
(free add-on for certain tests)
Additional Options
Re-Requisition Policy
Postmortem Testing
AmbryLink
All Sponsored Testing Programs
Test Orders
How to Order
AmbryPort®
(Order via Online Portal)
Sample Submissions
Order Sample Submission Kit
Sample Specimen Requirements
Forms
Test Forms
Billing + Insurance
Overview of Policies and Procedures
Preverification
Health Plan Requirements Guide
Cardiology, Neurology, and Rare Disease Health Plan Requirements Guide
Health Plan Coverage Map
Clinical Materials
Browse by Clinical Category
White Paper
Clinical Tools
Interactive Gene Coverage Tool
Telemedicine
Clinical Education
Webinars
Unparalleled Accuracy
Gene Classification
Candidate Disease Gene Discoveries
Variant Classification
Sanger Confirmation
Family Studies
Translational Genomics Lab
Peer-Reviewed Publications
Scientific Presentations
Scientific Posters
Browse Research by Conference
Oncology
Session # 18-9483
Are Gleason score and metastatic disease status important for men with prostate cancer undergoing multigene panel testing?
Speakers:
Michelle Jackson; Lauren Bowling; Jessica Profato; David Crawford
Conference:
AUA 2018
Date:
Monday, May 21, 2018 7:00pm - 9:00am
Read Abstract
View All Presentations
Close
Search Results
Start your search...
Previous
Next
Helpful Links
Order a Sample Kit
Forms
Contact Us
Test Menu
